New Study Shows Cortical Disarray Measurement (CDM®) Can Reflect Microscopic Patterns of Pathology in Frontotemporal DementiaResearch presented at ISFTD 2026 connects measurements from the living brain with disease patterns confirmed through postmortem analysis
Oxford Brain Diagnostics Appoints Healthcare AI Executive Jieun Choe as Chief Executive Officer and Board DirectorHealthcare AI and life sciences executive to scale its quantitative brain biology platform and advance the future of precision brain health
Oxford Brain Diagnostics Advances Vision for Measuring Brain Health and Neurodegenerative Disease with Five New Studies at AAIC 2026New findings demonstrate the potential of OBD's MRI-based Cortical Disarray Measurement (CDM®) technology to support patient identification, disease characterization, treatment monitoring, and therapeutic development across Alzheimer's disease
